IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) led to multiple drug repurposing clinical trials that have yielded largely uncertain outcomes. To overcome this challenge, we used IDentif.AI, a platform that pairs experimental validation with artificial intelligence (AI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Blasiak, Agata, Lim, Jhin Jieh, Seah, Shirley Gek Kheng, Kee, Theodore, Remus, Alexandria, Chye, De Hoe, Wong, Pui San, Hooi, Lissa, Truong, Anh T. L., Le, Nguyen, Chan, Conrad E. Z., Desai, Rishi, Ding, Xianting, Hanson, Brendon J., Chow, Edward Kai‐Hua, Ho, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823122/
https://www.ncbi.nlm.nih.gov/pubmed/33532594
http://dx.doi.org/10.1002/btm2.10196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823122/
https://www.ncbi.nlm.nih.gov/pubmed/33532594
http://dx.doi.org/10.1002/btm2.10196

Ejemplares similares